Bayer: new data on prostate cancer drug
(CercleFinance.com) - Bayer will present new data from its oncology programs at the forthcoming European Society of Medical Oncology (ESMO) congress, to be held in Madrid, on 20-24 October.
Bayer continues to focus on advancing prostate cancer care, from early to metastatic stages of the disease, through the development of innovative treatments aimed at prolonging survival, delaying disease progression and enabling patients to continue doing the things they love.
In particular, the laboratory will present results on darolutamide and on combined or layered treatments with radium-223 dichloride and enzalutamide in prostate cancer.
Bayer also remains committed to the fight against gastrointestinal cancer. New real-life data will be presented evaluating sequential treatment with regorafenib and trifluridine/tipiracil ± bevacizumab in patients with refractory mRCC.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Bayer continues to focus on advancing prostate cancer care, from early to metastatic stages of the disease, through the development of innovative treatments aimed at prolonging survival, delaying disease progression and enabling patients to continue doing the things they love.
In particular, the laboratory will present results on darolutamide and on combined or layered treatments with radium-223 dichloride and enzalutamide in prostate cancer.
Bayer also remains committed to the fight against gastrointestinal cancer. New real-life data will be presented evaluating sequential treatment with regorafenib and trifluridine/tipiracil ± bevacizumab in patients with refractory mRCC.
Copyright (c) 2023 CercleFinance.com. All rights reserved.